Dr.ย Pamelaย Munster
MD (Doctor of Medicine)
Professor of Medicine, Hematology & Oncology
corporate_fareUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Pamela Munster
MD (Doctor of Medicine)
Prof. Pamela N. Munster is a Professor of Medicine in Hematology and Oncology at the University of California, San Francisco (UCSF), and a senior medical oncologist at UCSF Health. She is a faculty member at the UCSF Helen Diller Family Comprehensive Cancer Center, where she leads the Early Phase Clinical Trials Unit and serves as Co-Director of the UCSF Center for BRCA Research.
Prof. Munster completed her medical degree at the University of Heidelberg, Germany, followed by residency training in internal medicine at the University of Wisconsin and a fellowship in haematology-oncology at Memorial Sloan Kettering Cancer Center. Over more than two decades at UCSF, she has built a clinical and research programme centred on breast cancer, early-phase oncology drug development, targeted therapy, and the biology of therapy resistance. Her scientific work focuses on epigenetic modification, epigenetic priming to improve treatment response, and BRCA-related cancer risk. She is also Co-Leader of UCSF's Developmental and Experimental Therapeutics Programme, and her academic contributions span peer-reviewed publications, Phase I trial leadership, and cancer patient advocacy including her book Twisting Fate: My Journey with BRCA.
CancerFax can coordinate medical-report review and second-opinion support for international patients seeking Prof. Munster's expertise, subject to hospital availability and case acceptance.
Why Consider Prof. Pamela Munster?
Prof. Munster is one of the United States' foremost academic medical oncologists in breast cancer and early-phase drug development, combining direct patient care with leadership in novel therapy research at one of the world's top cancer centres.
Areas of Specialisation
Breast cancer, early-phase drug development, BRCA research, and targeted or epigenetic therapies for advanced and treatment-resistant cancers
Prof. Munster's clinical and research work spans breast cancer medical oncology, the development of novel targeted and epigenetic therapies, and hereditary cancer risk management for patients with BRCA mutations.
Breast Cancer Medical Oncology
Comprehensive medical oncology care for all breast cancer subtypes, with particular expertise in advanced and treatment-resistant disease.
- arrow_rightHormone receptor-positive (HR+) and HER2+ breast cancer treatment planning
- arrow_rightTriple-negative breast cancer (TNBC) including immunotherapy-eligible cases
- arrow_rightCDK4/6 inhibitor-based regimens (palbociclib, ribociclib, abemaciclib)
- arrow_rightPI3K pathway inhibitors and AKT inhibitors for eligible patients
- arrow_rightNovel treatment strategies for cancers that have progressed on standard regimens
- arrow_rightBiomarker-driven selection of investigational agents through clinical trials
- arrow_rightEpigenetic priming approaches to restore treatment sensitivity
Early-Phase Clinical Trials & Developmental Therapeutics
Leadership in Phase I oncology studies and the early clinical development of investigational cancer agents.
- arrow_rightFirst-in-human and dose-escalation studies of novel cancer agents
- arrow_rightCombination strategies pairing investigational drugs with standard-of-care therapy
- arrow_rightEligibility assessment for patients who may benefit from early-phase trial access
- arrow_rightTargeted therapies under clinical investigation
- arrow_rightImmunotherapy combination strategies for solid tumours
- arrow_rightEpigenetic drug development and epigenetic priming research
BRCA Research & Hereditary Cancer Risk
Specialist care and research for patients with BRCA1/2 mutations and hereditary breast or ovarian cancer syndromes.
- arrow_rightTreatment planning for BRCA1/2-mutated breast and ovarian cancers
- arrow_rightPARP inhibitor therapy for eligible BRCA-mutation carriers
- arrow_rightHereditary cancer risk assessment and patient counselling
Procedures & Clinical Services
Medical oncology, early-phase trial enrolment, targeted therapy, and second-opinion services
Prof. Munster provides medical oncology care for breast and other solid tumour patients, leads early-phase clinical trial programmes, and offers expert second opinions for patients with complex or treatment-resistant cancers.
Breast Cancer Medical Oncology
Medical OncologyComprehensive systemic treatment planning and delivery for all breast cancer subtypes.
Early-Phase Clinical Trial Enrolment
Targeted TherapyEvaluation and enrolment for Phase I and early-phase investigational oncology trials.
Molecular Diagnostics & Biomarker Assessment
DiagnosisComprehensive molecular profiling to guide individualised treatment decisions.
Second Opinion Consultations
Second OpinionIndependent expert review of diagnosis, pathology, and treatment plan for breast and other solid tumour patients.
Research & Publications
Peer-reviewed contributions in breast cancer, early-phase drug development, and epigenetic oncology
Prof. Munster is a prolific academic oncologist whose research spans epigenetic therapy, breast cancer biology, therapy resistance, BRCA-related cancer, and Phase I drug development. Her work has been published in leading oncology journals and she has been a principal investigator on numerous early-phase clinical trials.
Prof. Munster's active Phase I trial leadership means eligible patients may be evaluated for access to investigational therapies not yet available outside clinical studies. CancerFax can facilitate case review to assess trial eligibility.
Education & Training
Prof. Munster completed her medical training in Germany and the United States, including a fellowship in haematology-oncology at Memorial Sloan Kettering Cancer Center.
Clinical Experience
Prof. Munster has spent the majority of her academic career at the University of California, San Francisco, where she has built one of the United States' leading early-phase oncology trial programmes alongside a clinical practice focused on breast and BRCA-associated cancers.
Languages & International
Prof. Munster consults in the following languages.
CancerFax can coordinate professional medical interpreter services for international patients requiring support in languages beyond English and German.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Pamela Munster
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Pamela Munster's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Pamela Munster's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Pamela Munster before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Pamela Munster's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Pamela Munster's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Pamela Munster's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Pamela Munster
Prof. Munster specialises in medical oncology with a focus on breast cancer, early-phase clinical trials, developmental therapeutics, BRCA-related cancer research, and targeted and epigenetic therapies for advanced or treatment-resistant cancers.
Prof. Munster is a Professor of Medicine at the University of California, San Francisco (UCSF), and practises at UCSF Health and the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California โ an NCI-designated comprehensive cancer centre.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Munster, subject to UCSF Health availability and case acceptance. Submit your reports through CancerFax and our team will manage the coordination process.
Prof. Munster cares for patients with breast cancer across all subtypes, including hormone receptor-positive, HER2-positive, triple-negative, and BRCA-associated breast cancer. She also evaluates patients with advanced solid tumours for early-phase clinical trial participation, and has expertise in BRCA-related ovarian cancer.
Yes. Prof. Munster is the Director of the Early Phase Clinical Trials Unit at UCSF and has been a Principal Investigator on multiple Phase I oncology studies. Her programme evaluates investigational agents for patients with advanced and treatment-resistant cancers. CancerFax can facilitate a case review to assess whether trial eligibility at UCSF may apply to your situation.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling, imaging, and treatment history. CancerFax will prepare the case for submission and coordinate the next steps. The consultation format and availability depend on UCSF Health scheduling and case suitability.
Prof. Munster's research centres on epigenetic modification and epigenetic priming strategies to overcome therapy resistance in breast cancer, novel targeted therapies, BRCA-related cancer biology, and early-phase oncology drug development. She is also Co-Director of the UCSF Center for BRCA Research.
Connect with Pamela Munster Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.